NSG™ Variants by Research Area

Innovative research models, built using the NOD scid gamma (NSG™) mouse

The versatility of NODscid gamma mice (005557) makes this strain the ideal platform to develop refined genetic models in multiple disease areas including immunology, cancer, transplantation and infectious disease. Innovative mouse strains, built on NSG™, with enhanced transgenic and targeted genetic modifications, allow sophisticated experimentation in multiple research areas.

Immunology

  • NSG™ HLA Class I transgenic strains (009617 and 014570), expressing A2 haplotypes 
    • Permit HLA restriction and enhance immune responses of human CD8 T cells (Strowig, et al. 2009; Shultz, et al. 2010)
  • NSG™ HLA Class II transgenic strains, expressing DR1 (012479) and DR4 (017637) haplotypes
    • Show enhanced antibody responses, and human CD4 T cells interact more effectively with human antigen presenting cells. A NRG DR4 transgenic strain, “DRAG” (017914), is accessible to for-profit entities (Danner R, et al. 2011)
  • NSG™ transgenic human membrane-bound Kit ligand (017830)
    • Improved myeloid engraftment (especially mast cells) and do not require pre-conditioning irradiation before engrafting human hematopoietic stem cells (Brehm, et al. 2012; Takagi, et al. 2012)

  • NSG™ transgenic human IL-3, CSF2, Kit ligand (013062)
  • NOD Rag gamma (NRG) (007799)
    • Radiation-resistant alternative to NSG™ mice
    • Equally effective at engrafting human hematopoietic stem cells and undergoing multilineage hematopoiesis as NSG™ (Pearson, et al. 2008)
  • NSG™ expressing EGFP (021937)
    • Expresses EGFP in all cells of the embryo and adult.
    • Facilitates visualization of allogeneic and xenogeneic grafts
  • NSG™ expressing human IL15 cytokine (030890) (030890)
    • Improved function and abundance of human NK cells following CD34 humanization (Brehm, et al. 2018)
  • NSG™ without MHC class I or class II molecules (025216)
  • NSG™ with Kit mutation (026622)

HIV & other infectious diseases

  • NSG™ HLA Class I transgenic strains (009617 and 014570), expressing A2 haplotypes
    • Allow HLA restriction of developing human CD8 cells in humanized models, and provide improved platforms for viral infection and vaccine models (Strowig, et al. 2009; Shultz, et al. 2010)
    • Antibody responses improved in a Dengue virus infection model (Jaiswal, et al. 2012)
  • NSG™ HLA Class II transgenic strains, expressing DR1 (012479) and DR4 (017637) haplotypes
    • Allow HLA restriction of developing human CD4 cells and improve interactions with antigen-presenting cells;
    • Enhanced IgG responses
  • NSG™ mice lacking MHC class I, NSG™ B2m (010636) and NSG™ (KbDb ) null (023848)

Cancer

  • NSG™ transgenic human IL-3, CSF2, Kit ligand (013062)
  • NSG™ Hprt mice (012480)
    • Facilitates isolation of human cancer cells from mouse stroma in vitro, and enable establishment of new patient-derived cell lines (Kamiyama, et al. 2013)
  • NSG™ expressing EGFP (021937)
    • Expresses EGFP in all cells of the embryo and adult
    • Facilitates visualization of allogeneic and xenogeneic grafts

Transplantation research

  • NSG™ without MHC class I or class II molecules (025216)
  • NSG™ lacking MHC class I, NSG™ B2m (010636) and NSG™ (Kb ) null (023848)
  • NSG™ lacking MHC class II (021885)
  • NSG™ expressing EGFP (021937)
    • Expresses EGFP in all cells of the embryo and adult
    • Facilitates visualization of allogeneic and xenogeneic grafts
  • NSG™-PiZ, with AAT deficiency (028842)

Diabetes

  • NRG Akita (014568)
    • Spontaneously develop hyperglycemia and allow engraftment of human pancreatic islets and stem cell therapies for Type 1 Diabetes (Brehm, et al. 2010)

Contact Us

micetech@jax.org
1.800.422.6423(US)
1.207.288.5845(International)